… what do payers really want to see?

Last fall's launch of a lower-priced monoclonal antibody to treat colorectal cancer raised the question: Has the biotech industry opened a price war? Not necessarily. Even if it were so, payers would view it with skepticism - despite all the talk about the cost of biologic drugs. So when a lower-cost product hits the market, if price isn't persuasive enough…